A retrospective global study of the prevalence of O-serotypes of invasive <i>Escherichia coli</i> disease in patients admitted to tertiary care hospitals

Invasive <i>Escherichia coli</i> disease (IED) is associated with high hospitalization and mortality rates, particularly among adults aged ≥60 years. O-antigens are virulence factors required for <i>E. coli</i> survival. To inform EXPEC9V development, a novel glycoconjugate vaccine targeting <i>E. coli</i> O-antigens that is no longer in active clinical development, this retrospective observational study describes O-serotype prevalence among <i>E. coli</i> isolates from IED patients. Eligible patients were identified from medical record databases (9 January 2018-8 November 2019) across 17 tertiary care hospitals in Europe, North America, and Asia. To estimate vaccine serotype coverage of EXPEC9V, <i>E. coli</i> isolates were O-serotyped using whole-genome sequencing and agglutination. Antimicrobial susceptibility testing was also performed. Nine hundred and two patients were enrolled, of whom 690 (76.5%) were aged ≥60 years. Common serotypes were O25, O2, O6, O1, O15, O75, O16, O4, and O18, with O25 being the most reported (17.3%). In patients aged ≥60 years, 422/637 <i>E. coli</i> isolates were EXPEC9V O-serotypes. EXPEC9V O-serotype prevalence did not substantially differ when stratified according to sex, presence of a positive blood culture, sepsis, fatality, or multidrug resistance. Consistent with previous studies, serotype O25 was most prevalent and associated with ~20% of cases. An EXPEC9V vaccine serotype coverage of 66.2% was observed for IED patients aged ≥60 years.

Authors

Institutions

Publication Details

Journal
Epidemiology and Infection
Published
2025-01-01
DOI
https://doi.org/10.1017/s0950268825100344
Citations
1
Primary Topic
Escherichia coli research studies
Type
article
Field-Weighted Citation Impact
1.80

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

A retrospective global study of the prevalence of O-serotypes of invasive Escherichia coli disease in patients admitted to tertiary care hospitals

Matthew Sims, Luis Martı́nez-Martı́nez, Jeff Powis, Michal Sarnecki et al.
1 citations
Epidemiology and Infection
Escherichia coli research studies
1.80
article

A retrospective global study of the prevalence of O-serotypes of invasive Escherichia coli disease in patients admitted to tertiary care hospitals

Matthew Sims, Luis Martı́nez-Martı́nez, Jeff Powis, Michal Sarnecki, Olivier Barraud, Jan Poolman, Philippe Lanotte, Florian Wagenlehner, Jeroen Geurtsen, Marc J. M. Bonten, Darren Abbanat, Tetsuya Matsumoto, Joshua T. Thaden, Joachim Doua, Bart Spiessens, Peter W. M. Hermans, Patricia Palacios, Oscar Go
article en
1 citations

Abstract

Invasive <i>Escherichia coli</i> disease (IED) is associated with high hospitalization and mortality rates, particularly among adults aged ≥60 years. O-antigens are virulence factors required for <i>E. coli</i> survival. To inform EXPEC9V development, a novel glycoconjugate vaccine targeting <i>E. coli</i> O-antigens that is no longer in active clinical development, this retrospective observational study describes O-serotype prevalence among <i>E. coli</i> isolates from IED patients. Eligible patients were identified from medical record databases (9 January 2018-8 November 2019) across 17 tertiary care hospitals in Europe, North America, and Asia. To estimate vaccine serotype coverage of EXPEC9V, <i>E. coli</i> isolates were O-serotyped using whole-genome sequencing and agglutination. Antimicrobial susceptibility testing was also performed. Nine hundred and two patients were enrolled, of whom 690 (76.5%) were aged ≥60 years. Common serotypes were O25, O2, O6, O1, O15, O75, O16, O4, and O18, with O25 being the most reported (17.3%). In patients aged ≥60 years, 422/637 <i>E. coli</i> isolates were EXPEC9V O-serotypes. EXPEC9V O-serotype prevalence did not substantially differ when stratified according to sex, presence of a positive blood culture, sepsis, fatality, or multidrug resistance. Consistent with previous studies, serotype O25 was most prevalent and associated with ~20% of cases. An EXPEC9V vaccine serotype coverage of 66.2% was observed for IED patients aged ≥60 years.

Epidemiology and InfectionVol. 153
Université de Tours (FR), Janssen (Belgium) (BE), Duke University (US), Oakland University (US), University of Toronto (CA), Justus-Liebig-Universität Gießen (DE), Instituto de Salud Carlos III (ES), Toronto East General Hospital (CA), University Medical Center (US), Instituto Maimónides de Investigación Biomédica de Córdoba (ES), Centre Hospitalier Universitaire de Tours (FR), Hôpital Bretonneau (FR), Human Vaccines Project Europe (NL), Janssen (Switzerland) (CH), Janssen (United Kingdom) (GB), Centre Hospitalier Universitaire de Limoges (FR), Hospital Universitario Reina Sofía (ES), Janssen (United States) (US), Beaumont Hospital, Troy (US), International University of Health and Welfare (JP)
Janssen Research and Development
Openalex Percentile: Top 14%
Escherichia coli research studies
1.80
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.